Prognostic impact of polypharmacy by drug essentiality in patients on hemodialysis

• DOI: 10.1038/s41598-021-03772-0
• Publication Date: 2021-12-20T11:13:41Z
• Authors: Mineaki Kitamura; Kosei Yamaguchi; Yuki Ota; Satoko Notomi; Maya Komine; Rika Etoh; Takashi Harada; Satoshi Funakoshi; Hiroshi Mukae; Tomoya Nishino
• Keywords: Male; Risk; Prescription Drugs; Science; Kaplan-Meier Estimate; Article; 03 medical and health sciences; 0302 clinical medicine; Renal Dialysis; Humans; Aged; Proportional Hazards Models; Retrospective Studies; Q; R; Middle Aged; Prognosis; 3. Good health; Cardiovascular Diseases; Polypharmacy; Medicine; Kidney Failure, Chronic; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Drugs, Essential

Abstract Although polypharmacy is common among patients on hemodialysis (HD), its association with prognosis remains unclear. This study aimed to elucidate the between number of prescribed medicines and all-cause mortality in HD, accounting for essential (i.e., antihypertensives, antidiabetic medicines, statins) non-essential medicines. We evaluated 339 who underwent maintenance HD at Nagasaki Renal Center July 2011 June 2012 followed up until 2021. After adjusting patient characteristics, regularly (10.0 ± 4.0) was not correlated (hazard ratio [HR]: 1.01, 95% confidence interval [CI] 0.97–1.05, p = 0.60). However, (7.9 3.6) (HR: 1.06, CI 1.01–1.10, 0.009). Adjusting were more than 10 found have a significantly higher probability those less five relative risk 2.01 (p 0.004). In conclusion, increases HD. As such, prescribing should be prioritized, clinical relevance each medicine reviewed by physicians pharmacists.